Literature DB >> 11182063

Clinical significance of MT1-MMP mRNA expression in breast cancer.

K Mimori1, H Ueo, C Shirasaka, M Mori.   

Abstract

Membrane-type 1 matrix metalloproteinase (MT1-MMP) is known as an activator of MMP-2. We reported that the expression of MT1-MMP is a powerful indicator of lymph node metastasis in gastric cancers. We now examined the possibility that MT1-MMP expression also is an indicator of lymph node metastasis in breast cancer. We examined the clinicopathologic significance of the expression of MT1-MMP mRNA in 53 breast cancer specimens by the semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) assay. The highest expression of MT1-MMP was found in those specimens showing lymph node metastasis and/or lymph vessel invasion. Therefore, an analysis of MT1-MMP can predict the presence of lymph node metastasis in breast cancer patients by RT-PCR assay in minute amounts of tissue. We believe this is an objective assay for determining the role of MT1-MMP for metastasis in patients with breast cancer.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11182063     DOI： 10.3892/or.8.2.401

Source DB:  PubMed          Journal:  Oncol Rep        ISSN： 1021-335X            Impact factor:   3.906


  10 in total

1.  Functional Production of Catalytic Domains of Human MMPs in Escherichia coli Periplasm.

Authors:  Dong Hyun Nam; Ki Baek Lee; Xin Ge
Journal:  Methods Mol Biol       Date:  2018

2.  Similar expression profiles of a core of genes and proteins in cells that have acquired a metastatic phenotype, genetically or by in vivo evolution.

Authors:  Laila Illán Rubio; Bertrand Tavitian; Elina Zueva
Journal:  Clin Exp Metastasis       Date:  2009-11-11       Impact factor: 5.150

3.  New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.

Authors:  Laetitia Devy; Daniel T Dransfield
Journal:  Biochem Res Int       Date:  2010-10-28

4.  Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis.

Authors:  Sylvia Fong; Yoko Itahana; Tomoki Sumida; Jarnail Singh; Jean-Philippe Coppe; Yong Liu; Peter C Richards; James L Bennington; Nancy M Lee; Robert J Debs; Pierre-Yves Desprez
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-24       Impact factor: 11.205

Review 5.  Breast cancer progression: insights into multifaceted matrix metalloproteinases.

Authors:  Vincent Chabottaux; Agnès Noel
Journal:  Clin Exp Metastasis       Date:  2007-10-30       Impact factor: 5.150

6.  Laparoscopic surgery minimizes the surgical manipulation of isolated tumor cells leading to decreased metastasis compared to open surgery for colorectal cancer.

Authors:  Sayuri Akiyoshi; Koshi Mimori; Tomoya Sudo; Fumiaki Tanaka; Kohei Shibata; Masaki Mori
Journal:  Surg Today       Date:  2012-10-27       Impact factor: 2.549

7.  Expression of metalloproteases and their inhibitors in primary tumors and in local recurrences after mastectomy for breast cancer.

Authors:  José M del Casar; Guillermo Carreño; Luis O González; Sara Junquera; Salomé González-Reyes; José M González; Miguel Bongera; Antonio M Merino; Francisco J Vizoso
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-30       Impact factor: 4.553

8.  Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins.

Authors:  David Alonso-Escolano; Alex Y Strongin; Ada W Chung; Elena I Deryugina; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2003-12-22       Impact factor: 8.739

9.  The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis.

Authors:  Bernard Têtu; Jacques Brisson; Chang Shu Wang; Hélène Lapointe; Geneviève Beaudry; Caty Blanchette; Dominique Trudel
Journal:  Breast Cancer Res       Date:  2006-06-15       Impact factor: 6.466

10.  Overexpression of matrix metalloproteinases and their inhibitors in mononuclear inflammatory cells in breast cancer correlates with metastasis-relapse.

Authors:  L O González; I Pidal; S Junquera; M D Corte; J Vázquez; J C Rodríguez; M L Lamelas; A M Merino; J L García-Muñiz; F J Vizoso
Journal:  Br J Cancer       Date:  2007-09-11       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.